TRANSIENT ISCHEMIC ATTACK MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-157348 |   Health Care

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Transient Ischemic Attack Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET

7.1 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Abbott Laboratories (United States)

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Boston Scientific Corporation (United States)

16.3 Cardinal Health, Inc. (United States)

16.4 GE Healthcare (United States)

16.5 Medtronic plc (Ireland)

16.6 Merck & Co. Inc. (United States)

16.7 Siemens Healthineers AG (Germany)

16.8 LivaNova PLC (United Kingdom)

16.9 Bayer AG (Germany)

16.10 Cigna (United States)

16.11 Novartis AG (United States)

16.12 Pfizer Inc. (United States)

16.13 Daiichi Sankyo Co., Ltd. (Japan)

16.14 electroCore, Inc. (United States)

16.15 Eli Lilly and Company (United States)

16.16 Novo Nordisk A

16.17 S (Denmark)

16.18 Sanofi SA (France)

16.19 Stryker Corporation (United States)

16.20 Terumo Corporation (Japan)

16.21 Zocere, Inc. (Mexico)

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By End Users
Hospitals & Clinics
Diagnostic Centers
Research Laboratories

By Age Group
0–18 years
19–40 years
41–60 years
60+ years

By Diagnosis Type
Imaging Techniques
Computed Tomography (Ct) Scan
Carotid Duplex Scanning
Magnetic Resonance Imaging
Echocardiography
Arteriography

By Treatment
Medication {Anti-Platelet Drugs Anticoagulants Thrombolytic Agents}
Surgery
Angioplasty

Companies

Abbott Laboratories (United States)
Boston Scientific Corporation (United States)
Cardinal Health, Inc. (United States)
GE Healthcare (United States)
Medtronic plc (Ireland)
Merck & Co. Inc. (United States)
Siemens Healthineers AG (Germany)
LivaNova PLC (United Kingdom)
Bayer AG (Germany)
Cigna (United States)
Novartis AG (United States)
Pfizer Inc. (United States)
Daiichi Sankyo Co., Ltd. (Japan)
electroCore, Inc. (United States)
Eli Lilly and Company (United States)
Novo Nordisk A
S (Denmark)
Sanofi SA (France)
Stryker Corporation (United States)
Terumo Corporation (Japan)
Zocere, Inc. (Mexico)

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.